



# Network data strategy: Analysis of data and use of tools, Knowledge and change management

28 November 2024

Session 4 of the HMA/EMA Big Data Stakeholder Forum: Unlocking the value of data with the EMRN data strategy

Presented by Kristine Aasen, Senior Enterprise Architect, NOMA Network Data Board member and NICTAC member







### About the speaker



### **Kristine Aasen**

Enterprise Architect, The Norwegian Medical Products Agency

Kristine Aasen has the role as senior enterprise architect in NOMA. In this role she is working for national and international interoperability through data standardisation. Kristine has a master's degree in information science, and she is certified for TOGAF and ITIL. Her experience spans from work with master data, to primary use of data in hospital and to secondary use of data for research. Kristine is a member of the European Medicines Agency's Network ICT Advisory Committee and has been a member of the Network Data Board.

Contact

email: <u>kristine.aasen@noma.no</u> Linkedin: <u>Kristine Aasen | LinkedIn</u>





# EMRN Data strategy goal and objectives

The EMRN has implemented Artificial Intelligence for maximising evidence generation, increasing productivity, data insights and strengthened decision-support.

Obj. 10 – Additional business value is generated by using and interconnecting EMRN data assets

Obj. 11 - Value from information and data available in unstructured sources is generated

Obj. 12 – Tools for analysis are available for the EMRN to enrich and improve scientific, regulatory, and corporate processes

### AI Experimentation at EU Network: examples





EUROPEAN MEDICINES AGENCY

**ChatGPT@EMA pilot** 

A pilot to explore ChatGPT use at EMA

TTS automated case adjudication

Can we use ML to streamline the review of ICSRs?

Luis Pinheiro, EMA and Julie Durand, EMA

Jakub Hasiec, Data Scientist - Analytics Centre of Excellence, TDT, EMA





PHAIR: PHarmacovigilance by AI Real-time

Jesper Kjaer

Inhouse LLM at DKMA

As a tool to drive GDPR compliant digital transformation



XLMeQA + NLP Platform + MedDRA Terms

Ongoing AI projects at AEMPS

Ana López de la Rica, AEMPS

### fimea

#### **Regulatory memory machine**

Customized LLM applications to search from regulatory documents

Antti Hyvärinen, Elina Asikanius



#### AI@MPA

Putting regulatory AI in production for EU network use

Gabriel Westman

Head of Artificial Intelligence, Swedish Medical Products Agency

#### M-RECON

Medicines regulatory context engine

#### **PICROSS**

Product information cross search

#### PACKSIM

Mock-up similarity search

#### PhaVAI triage

PI for triage of ADR reports



BMG-KIMERBA - intelligent in-house automation of regulatory workflows

**BMG-BLOODVIR** - knowledge accumulation for AI assessment

BMG-RENUBIA - assessment and validation of AI-based tools in medicinal products

Classified as public by the European Medicines Agency



## NOMA Project proposals and use cases for analytics tool

Use case 1: NOSMP – Monitoring the supply chain for preparedness and shortages


Use case 2: NODAMED - Monitoring safety reports for signal detection

Use case 3: Inspections – Monitoring activity in NMVS for targeted inspection






### Advanced analytics tool incl. AI - Application components




## NOMA's Cloud Platform (AS-IS)






## Expanding NOMA's Cloud Platform (TO-BE)





### Use Case 1: NOSMP - monitor and prevent shortages






### Values and benefits of AI and analytics tools







## AI and analysis tools - success factors



- > A holistic view on the business
- Standardised and cleansed data
- Clear use cases and business objectives
- Pilots and validation
- Monitoring and maintenance
- Strong governance and access control
- > Digital maturity

### EU NTC training catalogue



#### Digital and Big Data training offers

#### **EU Network Training Centre** Newsletter

Training by the Network for the Network

BIG DATA

DARWIN EU Autumn School: Population-level disease epidemiology and patient-level characterisation

This is the second webinar in a series to increase the understanding of different types of analyses conducted through the DARWIN EU® Network.





04/11/2024 - 05/11/2024



date



How to ensure data quality in the generation of real-world evidence (RWE)

The course has been developed by the EMA Data Analytics and Methods Task Force. Real-World Evidence Workstream in liaison with Healthcare Data colleagues at EMA.



First modules of the Data Science curriculum now available

The Data Science curriculum is a series of trainings on data science that have been specifically designed for the European Medicines Regulatory Network (EMRN) to enhance knowledge and develop skills in this field.

Accessing EU NTC training

BIG DATA, AI



DIGITAL

Thinking



In this new Digital Academy 30-minute in-

teractive e-learning module and accompa-

learn about Design Thinking.

nying learning resources collection, you will

Digital Academy intro module and collection on Design







ARTIFICIAL INTELLIGENCE, PHARMACOVIGILANCE

#### Challenges and future role of artificial intelligence chine learning in pharmacovigilance

This is a recording of a webinar held on 26 July 2024 on the challenges and future role of artificial intelligence and machine learning in pharmacovigilance. The webinar was delivered by Dr Dirk Mentzer, Head of Safety of Biomedicines and Diagnostics Division. Paul Ehrlich Institut.



DIGITAL, DATA, DATA PROTECTION

#### Digital Academy intro modules and collections on Data **Literacy and Data Protection**

Increase your data literacy and data protection skills with the new Digital Academy interactive e-learning modules and accompanying learning resource collections



REAL-WORLD EVIDENCE, METHODOLOGY

#### Joint HMA/EMA Big Data Steering Group Workshop on RWE methods: Harnessing Real-World Data for Regulatory Use

The training consists of a recording of a one-day hybrid Big Data Steering Group (BDSG) workshop held on 14 June 2024. The programme was developed by the EMA Data Analytics and Methods Task Force, Real-World Evidence Workstream.



BIG DATA, RWD, RWE

RWD in support of regulatory work in paediatrics - example of the RWD extrapolation framework with a pilot study in dermatomyositis and polymyositis - Real World Academy session 4

This 4th session of the Real World Academy focuses on the use of RWD to inform and support regulatory work in paediatrics.












## From my bookshelf











# Thank you for listening

Disclaimer: Some of this slides are created with help of AI ;-)

### Further information

See websites for contact details

Heads of Medicines Agencies www.hma.eu European Medicines Agency www.ema.europa.eu







# Stay up to date

- Big Data webpage
- Big Data Highlights resubscribe here
- > EMA events
- > Social media







